Skip to main content
AmigoFish

Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking

From The BioCentury Show · · 35 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with GSK and BMS. Under the leadership of Frank Jiang, EVP and chief strategy officer, Hengrui is engaging in a range of dealmaking and using its partnerships as stepping stones toward its goal of becoming one of the top biopharma companies in the world. In conversation with Executive Editor Jeff Cranmer on The BioCentury Show, Jiang describes the evolution of China’s biotech ecosystem — and Hengrui's — toward first-order innovation and the changing nature of deals in China, from straightforward licensing deals with “safe money” to NewCo deals and “co-co” partnerships.

View full story: https://www.biocentury.com/article/659912

#ChinaBiotech #BiopharmaInnovation #DrugDevelopment #StrategicPartnerships #GlobalBiotech

00:00 - Introduction 01:32 - Evolution of China Biotech 08:43 - China Deals 17:23 - Hengrui’s Evolution 24:43 - Shareholder Base 26:42 - Deals

Back to The BioCentury Show · Report a problem